[Featured Stock] Shaperon, World's First Inflammation Complex Inhibition Mechanism... Preparing to Surpass Steroids

Shaperon is showing strong performance. Expectations are rising for the technology transfer of 'NuGel,' the world's first atopic dermatitis treatment with an inflammation complex inhibition mechanism that demonstrates anti-inflammatory effects comparable to steroid drugs without side effects such as immune suppression.

As of 10:54 AM on the 2nd, Shaperon is trading at 3,740 KRW, up 6.86% from the previous trading day.

Shaperon announced its participation in the '2025 JP Morgan Healthcare Conference.' It is expected that discussions on technology transfer with numerous global pharmaceutical companies will intensify, focusing on the clinical results of the atopic dermatitis treatment NuGel.

Shaperon plans to meet with various global pharmaceutical and biotech companies to introduce its key pipelines and engage in in-depth discussions for technology transfer. Meetings are planned with many companies that have shown interest at overseas conferences regarding the Part 1 clinical results of NuGel, an atopic dermatitis treatment currently undergoing Phase 2b clinical trials in the United States.

NuGel is the world's first atopic dermatitis treatment with an inflammation complex inhibition mechanism. Unlike existing inflammation complex inhibitors that suppress the activation stage of inflammation, NuGel acts doubly at both the initiation and amplification stages of inflammation, enabling effective inflammation control. NuGel shows anti-inflammatory effects comparable to steroid drugs but does not exhibit side effects such as immune suppression, allowing for long-term use. Therefore, it is expected to become an effective treatment alternative for patients with mild to moderate atopic dermatitis.

The Part 1 Phase 2b clinical trial of NuGel conducted in the United States includes diverse ethnic groups, including Caucasians, and allows for safety and efficacy analysis by dosage, attracting attention from global pharmaceutical companies.

A Shaperon representative stated, "We have completed recruitment of all patients scheduled for Part 1 and successfully finished dosing. No serious adverse effects were observed in any dosing group under double-blind conditions, so we expect smooth progress into Phase 2 clinical trials."

They added, "Through active sales activities, we will achieve technology transfer results for key pipelines including NuGel. We will also accelerate research and development for each pipeline to fully commence profit generation."